OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
DVAX
Dynavax Technologies Corp.
Common Stock
10.26
-0.14
-1.35%
Delayed (15 Min) Trade Data: 12:00am 10/31/2025
Dynavax Technologies Corp.
2100 Powell Street
Suite 720
Emeryville, CA 94608
www.dynavax.com
(510) 848-5100
Business Description
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
CIK
0001029142
Fiscal Year End
12/31
Company Officers & Contacts
Dino Dina
President, CEO
William J. Dawson
CFO
Board of Directors
Not available
Other Company Insiders
Not available
Service Providers
Not available
Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
DE, US
Employees
Not Available
Shell
No
Products and Services
Not available
Company Facilities
Not available
Loading...
Symbol
OTCM
Last
54.40
Change
1.52 (2.87%)
Bid
54.40
Ask
55.00
Volume
19777
Time
00:00
© 2025 OTC Markets Group Inc.
Terms of ServiceLinking TermsTrademarksPrivacy StatementCode of ConductRisk WarningSupported Browsers